Related Experiment Video
Updated: Mar 1, 2026

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
Published on: October 1, 2019
Elevation of plasma oncostatin M in heart failure
Damien Gruson1,2, Benjamin Ferracin2, Sylvie A Ahn3
1Pôle de recherche en Endocrinologie, Diabète et Nutrition, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires St-Luc & Université Catholique de Louvain, Brussels, Belgium.
Aim:
Oncostatin M (OSM) is an inflammatory cytokine of the gp130 family. OSM could participate in adverse cardiovascular remodeling through regulation of FGF23.
Materials & Methods:
OSM levels were determined in 80 heart failure patients with reduced left ventricular ejection fraction (HFrEF).
Results:
OSM levels are significantly increased in HFrEF patients compared with healthy subjects. We have also demonstrated that, in HFrEF patients, plasma OSM levels are correlated to parathyroid hormone PTH(1-84) and 1,25(OH)2D, two other biomarkers related to bone and mineral metabolism and associated to adverse cardiovascular outcomes.
Conclusion:
OSM concentrations are elevated in HFrEF patients and could interplay with parathyroid hormone and vitamin D impacting cardiovascular function. Nevertheless, the prognostic value of OSM testing appears limited.
Related Concept Videos
Heart Failure II: Pathophysiology
Heart Failure Drugs: Inotropic Agents
Heart Failure III: Clinical Manifestations
Pathophysiology of Heart Failure
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure VII: Nursing Interventions
